Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

09 Jul 2024
·
Deals
www.pharmaceutical-technology.com
Drug ApprovalImmunotherapyAcquisitionLicense out/in
Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m
Preview
Source: Pharmaceutical Technology
QARZIBA is indicated to treat high-risk neuroblastoma in patients aged 12 months and above. Credit: Kateryna Kon/Shutterstock.
Ligand Pharmaceuticals has announced a definitive agreement for the acquisition of the complete outstanding shares of Austria-based biopharmaceutical company APEIRON Biologics in a $100m cash deal.
The deal also includes future payments based on commercial and regulatory milestones.
The strategic move will grant Ligand royalty rights to QARZIBA (dinutuximab beta), a treatment for high-risk neuroblastoma in patients aged 12 months and above.
It is indicated for those who have responded to induction chemotherapy, undergone myeloablative therapy and stem cell transplantation, and with a history of relapsed or refractory neuroblastoma with or without residual disease.
APEIRON co-developed QARZIBA, which received the European Medicines Agency approval in 2017. This therapy is currently available in more than 35 countries.
See Also:How will a Labour government support the UK clinical trials industry?
Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m
Preview
Source: Pharmaceutical Technology
TLC-2716 by OrsoBio for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia): Likelihood of Approval
Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m
Preview
Source: Pharmaceutical Technology
The company receives royalties on the product’s net sales outside mainland China from Recordati and within mainland China from BeiGene.
Ligand will make further payments based on commercial and regulatory milestones, with potential payments up to $28m by either 2030 or 2034 on QARZIBA royalties exceeding preset thresholds.
The agreement received unanimous approval from the board of directors of Ligand and the supervisory board of APEIRON.
The acquisition will conclude in July 2024.
Ligand is also investing $4m in invIOs Holding, an APEIRON spin-off, under a stock purchase agreement.
This funding will support the research and development of three early-stage immuno-oncology assets.
Ligand CEO Todd Davis stated: “The addition of QARZIBA to our commercial royalty portfolio further supports our growth strategy to invest in high-value medicines that deliver significant clinical value and generate predictable and long-term revenue streams for our investors.
“QARZIBA is the only immunotherapy for high-risk neuroblastoma marketed across Europe and in other parts of the world. We believe this drug will be a meaningful contributor to our royalty revenue, which is now driven by a diversified portfolio of 12 key commercial-stage products.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.